The global respiratory inhaler devices market is set for substantial growth over the next decade, with projections indicating a rise from USD 37,258.5 million in 2023 to an impressive USD 60,114.7 million by 2033. This growth reflects a robust Compound Annual Growth Rate (CAGR) of 4.90% throughout the forecast period.
The increasing prevalence of respiratory diseases worldwide is a significant driver behind this market expansion. As chronic respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD) continue to rise, the demand for advanced and efficient respiratory care solutions is intensifying. Inhaler devices, which are essential for managing symptoms and providing relief, are thus experiencing concurrent growth.
“Inhaler devices are crucial for managing chronic respiratory conditions, and their evolving technology is key to enhancing patient outcomes,” says an FMI analyst. “Research and development activities focused on smart inhaler devices and new product innovations will drive growth in the market.”
Key Market Insights:
- Regional Dominance: North America is anticipated to lead the market, with over 45% revenue share by the end of the forecast period.
- Rapid Growth in India: The Indian market is projected to exhibit the fastest CAGR of 6.10% during the forecast period.
- Growth in China: China is expected to experience a CAGR of 5.20% in the respiratory inhaler devices market.
- Product Type: Metered Dose Inhalers are projected to hold a 75.4% market share by 2033.
- Disease Indication: Asthma is expected to dominate the market with a 66.8% revenue share by 2033.
Get Your Business Strategy Instantly Access the Full Report
Competitive Landscape:
The respiratory inhaler devices market is highly competitive, featuring several key players focused on innovation and product development. Major companies include AstraZeneca, Beximco Pharmaceuticals Ltd., Cipla Ltd., GlaxoSmithKline plc., OMRON Healthcare Europe B.V., PARI Medical Holding, Teva Pharmaceutical Industries Ltd., Koninklijke Philips N.V., Boehringer Ingelheim GmbH, and Merck & Co., Inc.
Recent Developments:
- In December 2020, OMRON Healthcare launched WheezeScan for children with asthma to accurately detect wheezing and reduce misdiagnosis.
- In March 2021, AstraZeneca PLC initiated a Phase 3 clinical trial in the US and Mexico to assess the safety and effectiveness of budesonide/glycopyrronium/formoterol inhalers in adolescents and adults with chronic asthma. The trial is expected to complete in September 2023.
- In May 2022, Alkem introduced “Innohaler,” its first inhalation device for asthma and COPD patients.
Market Segmentation:
- By Product: Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers (Compressed Air, Ultrasonic, Mesh)
- By Technology: Manually Operated Inhaler Devices, Digitally Operated Inhaler Devices
- By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension, Others
- By Region: North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East, and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
